Dune Medical receives FDA clearance for MarginProbe breast cancer surgery system

Dune Medical Devices has announced it has received FDA approval for its MarginProbe system for use in breast cancer surgery, according to a news release.

The system, an intra-operative tissue assessment tool for early-stage breast cancer surgery, is intended to enable real-time detection of cancer at or near the surface of excised tissue specimens during breast cancer surgery. MarginProbe uses electromagnetic "signatures" to identify healthy and cancerous tissue during lumpectomy.

 

"The MarginProbe system was developed to address one of the longest standing unmet medical needs in the breast cancer surgical community," said Daniel Levangie, CEO of Dune Medical Devices, in the release. "We have received resounding support from clinicians, advocacy organizations and patients alike, who have recognized the value of MarginProbe and intra-operative, real-time detection of cancer on the margin to potentially improve patient outcomes."

 

Dune Medical Devices has offices in the United States, Israel and Switzerland.

 

Related Articles on FDA Clearances:

Medical Modeling Receives FDA Clearance for Virtual Surgical Planning System

EndoChoice Receives FDA Clearance for Water Bottle Cap Irrigation System

Avinger Receives FDA Clearance for Smaller, Longer Optical Coherence Tomography Catheter

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars